Enzymatica has established a scientific advisory board. The board consists of four established and well-known scientists, with particular focus on enzyme technology and infectious diseases. The purpose of the Scientific Advisory Board is in general to assist and advice Enzymaticas board of management in research-related issues and specifically to evaluate and advice on future clinical research and pipeline development.
- It is part of our strategy to deliver and develop products with strong scientific support. We have therefore decided to establish a renowned Scientific Advisory Board to be linked to our operations in order to assure the quality of our clinical research and product development, said Michael Edelborg Christensen, CEO of Enzymatica.
The Scientific Advisory Board will primarily focus on giving advice to Enzymaticas long-term strategy and priorities of potential product candidates in the pipeline, scientific review and advisory services for clinical trials program. In addition, the Council will assist the company in matters of design and execution of clinical trials and make recommendations for final product packaging, sales and marketing.
The members of Enzymaticas Scientific Advisory Board consists of:
Thomas is an associate professor of medical microbiology and has more than 15 years of experience in research on bacterial infections and antibacterial molecules. Thomas has postdoctoral training from the University of Oxford and lead since 2008, a research team at the Faculty of Medicine at Lund University.
Mats has a PhD in enzyme technology from Lund University and has 20 years of experience in research on enzymes and more than 10 years experience in pharmaceutical research and development of biotechnology companies, most recently from Alligator Bioscience AB.
Göran is a physician at the infectious diseases clinic in Lund with clinical experience in evaluation and treatment of infectious diseases 15 years ago. Göran holds an MD degree in the subject Infection Immunology. Current research is done in collaboration with the departments of Clinical Immunology and Rheumatology in Lund.
Lena is an associate professor of immunopharmacology at Lund University, and since 2008, research manager at BMC in Lund. She is the author of more than 30 scientific articles on inflammatory diseases. Her research area concerns the mechanisms and drug development in airway inflammation and cold induced asthma and COPD.
For more information, contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ), +46 (0) 768 144 166, firstname.lastname@example.org